Johnson & Johnson Lifts Full-Year Outlook Following Second-Quarter Beat
Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. The healthcare products conglomerate now anticipates adjusted earnings of $11.60 to $11.75 per share for 2026, up from its previous projection of $11.45 to $11.65. Sales are pegged between $100.8 billion and $101.4 billion, compared with the prior guidance of $100.3 billion to $101.3 billion. The consensus on FactSet is for non-GAAP EPS of $11.59 and sales of $101.06 billion for the year. "Johnson & Johnson delivered strong second-quarter results," Chief Executive Joaquin Duato said in a statement. "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our company's 140-year history." For the quarter ended June 28, Johnson & Johnson's adjusted EPS increased to $2.90 from $2.77 last year, topping the Street's view for $2.85. Sales improved 6.6% to $25.31 billion, surpassing the average analyst estimate of $25.02 billion. Innovative medicine sales grew 7.8% to.
Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses.
The healthcare products conglomerate now anticipates adjusted earnings of $11.60 to $11.75 per share for 2026, up from its previous projection of $11.45 to $11.65.
Sales are pegged between $100.8 billion and $101.4 billion, compared with the prior guidance of $100.3 billion to $101.3 billion.
The consensus on FactSet is for non-GAAP EPS of $11.59 and sales of $101.06 billion for the year. "Johnson & Johnson delivered strong second-quarter results," Chief Executive Joaquin Duato said in a statement. "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our company's 140-year history." For the quarter ended June 28, Johnson & Johnson's adjusted EPS increased to $2.90 from $2.77 last year, topping the Street's view for $2.85.
Sales improved 6.6% to $25.31 billion, surpassing the average analyst estimate of $25.02 billion.
Innovative medicine sales grew 7.8% to.